Code of Federal Regulations: Containing a Codification of Documents of General Applicability and Future Effect as of December 31, 1948, with Ancillaries and IndexDivision of the Federal Register, the National Archives, 2001 Special edition of the Federal Register, containing a codification of documents of general applicability and future effect ... with ancillaries. |
No grāmatas satura
1.–5. rezultāts no 59.
18. lappuse
... abbreviated new drug ap- plication to establish and maintain records and make reports to FDA of all serious , unexpected adverse drug expe- riences associated with the use of their drug products . Any person subject to the reporting ...
... abbreviated new drug ap- plication to establish and maintain records and make reports to FDA of all serious , unexpected adverse drug expe- riences associated with the use of their drug products . Any person subject to the reporting ...
21. lappuse
... abbreviated new drug application for these prod- ucts . Any such drug product then on the market which is not the subject of an application submitted for the drug product shall be subject to regulatory procedures under section 505 of ...
... abbreviated new drug application for these prod- ucts . Any such drug product then on the market which is not the subject of an application submitted for the drug product shall be subject to regulatory procedures under section 505 of ...
22. lappuse
... abbreviated new drug application : ( i ) A statement that the applicant will establish procedures to test each lot of digoxin tablets prior to releasing the batch for distribution to assure that the batch meets all of The United States ...
... abbreviated new drug application : ( i ) A statement that the applicant will establish procedures to test each lot of digoxin tablets prior to releasing the batch for distribution to assure that the batch meets all of The United States ...
23. lappuse
... abbreviated new drug application containing adequate data to demonstrate the bioavailability of the reformulated product . Food and Drug Administration approval of the supplement is required before the re- formulated product is marketed ...
... abbreviated new drug application containing adequate data to demonstrate the bioavailability of the reformulated product . Food and Drug Administration approval of the supplement is required before the re- formulated product is marketed ...
27. lappuse
... Abbreviated new drug applications shall be submitted to the Food and Drug Administration , Center for Drug Evaluation and Research , Office of Ge- neric Drugs , 5600 Fishers Lane , Rock- ville , MD 20857 . ( g ) All samples of digoxin ...
... Abbreviated new drug applications shall be submitted to the Food and Drug Administration , Center for Drug Evaluation and Research , Office of Ge- neric Drugs , 5600 Fishers Lane , Rock- ville , MD 20857 . ( g ) All samples of digoxin ...
Citi izdevumi - Skatīt visu
Bieži izmantoti vārdi un frāzes
abbre abbreviated application abbreviated new drug acid active ingredient added adverse drug experience agency amended application or abbreviated aspirin Authority citation revised bacitracin bioavailability bioequivalence cation Center for Drug chapter clinical investigation consult a doctor contains the following Department dient digoxin dosage form dose Drug Administration drug application drug prod drug product Drug products containing effective date ephedrine Federal Acquisition Regulation Federal Food FEDERAL REGISTER Food and Drug grams gredients homosalate ingre introductory text investigational new drug labeling marketing ment milligrams milligrams in 24 misbranded neomycin Office OMB number oral dosage orphan drug OTC drug product over-the-counter paragraph patent percent plication polymyxin protocol recognized as safe Redesignated reference listed drug regulations request safe and effective safety salicylate Sodium sponsor submission submitted sulfate sunscreen taining tion tive treatment unless directed warning
Populāri fragmenti
10. lappuse - Commissioner finds such requirements are not necessary for the protection of the public health by reason of the drug's toxicity or other potentiality for harmful effect, or the method of its use, or the collateral measures necessary to its use, and he finds that the drug is safe and effective for use in self-medication as directed in proposed labeling.
337. lappuse - Advisory Council on Historic Preservation African Development Foundation Federal Acquisition Regulation Agency for International Development, United States Federal Acquisition Regulation Agricultural Marketing Service Agricultural Research Service Agriculture Department Agricultural Marketing Service Agricultural Research Service Animal and Plant Health Inspection Service Chief Financial Officer, Office of Commodity Credit Corporation Cooperative State Research, Education, and Extension Service Economic...
154. lappuse - ... drug, based on a fair evaluation of all material facts, is false or misleading in any particular and was not corrected within a reasonable time after receipt of written notice from the Secretary specifying the matter complained of. Any order under this subsection shall state the findings upon which it is based.
147. lappuse - ... consisting of adequate and well-controlled investigations, including clinical investigations, by experts qualified by scientific training and experience to evaluate the effectiveness of the drug involved, on the basis of which it could fairly and responsibly be concluded by such experts that the drug will have the effect it purports or is represented to have under the conditions of use prescribed, recommended, or suggested in the labeling or proposed labeling thereof.
321. lappuse - XXVI Office of Inspector General, Department of Agriculture (Parts 2600—2699) XXVII Office of Information Resources Management, Department of Agriculture (Parts 2700—2799) XXVIII Office of Operations, Department of Agriculture (Parts 2800— 2899) XXIX Office of Energy, Department of Agriculture (Parts 2900—2999) XXX Office of the Chief Financial Officer, Department of Agriculture (Parts 3000—3099) XXXI Office of Environmental Quality, Department of Agriculture (Parts 3100—3199) XXXII Office...
90. lappuse - Non-Therapeutic Biomedical Research Involving Human Subjects (Non-Clinical Biomedical Research) 1. In the purely scientific application of medical research carried out on a human being, it is the duty of the physician to remain the protector of the life and health of that person on whom biomedical research is being carried out. 2. The subjects should be volunteers — either healthy persons or patients for whom the experimental design is not related to the patient's illness. 3. The investigator or...
84. lappuse - The investigator is required to furnish his reports to the sponsor of the drug who is responsible for collecting and evaluating the results obtained by various investigators. The sponsor is required to present progress reports to the Food and Drug Administration at appropriate intervals not exceeding 1 year.
90. lappuse - Informed of the alms, methods, anticipated benefits and potential hazards of the study and the discomfort It may entail. He or she should be informed that he or she Is at liberty to abstain from participation in the study and that he or she is free to withdraw his or her consent to participation at any time.
254. lappuse - Act. (b) References in this part to regulatory sections of the Code of Federal Regulations are to chapter I of title 21, unless otherwise noted. [45 FR 36390, May 30, 1980; 46 FR 8979, Jan. 27, 1981] 5 50.3 Definitions As used in this part: (a) Act means the Federal Food, Drug, and Cosmetic Act, as amended (sees. 201-902, 52 Stat. 1040 et seq. as amended (21 USC 321-392)). (b) Application for research or marketing permit...
309. lappuse - If offered for use in arthritis or rheumatism, in juxtaposition therewith, the statement: Caution — If pain persists for more than 10 days, or redness is present, or in conditions affecting children under 12 years of age consult a physician immediately.